Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Screening asymptomatic people at high risk for hepatitis C. The case for.

Literature DB >> 8646052

Screening asymptomatic people at high risk for hepatitis C. The case for.

C A Seymour¹.

Abstract

Entities: Species

Mesh：

Year: 1996 PMID： 8646052 PMCID： PMC2351003 DOI： 10.1136/bmj.312.7042.1347

Source DB: PubMed Journal: BMJ ISSN： 0959-8138

× No keyword cloud information.

13 in total

1. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials.

Authors: F Tinè; S Magrin; A Craxì; L Pagliaro
Journal: J Hepatol Date: 1991-09 Impact factor: 25.083

2. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b.

Authors: G Saracco; F Rosina; M L Abate; L Chiandussi; V Gallo; E Cerutti; A Di Napoli; A Solinas; A Deplano; A Tocco
Journal: Hepatology Date: 1993-12 Impact factor: 17.425

3. Interferon and hepatitis C.

Authors: N Terrault; T Wright
Journal: N Engl J Med Date: 1995-06-01 Impact factor: 91.245

4. Understanding hepatitis B virus infection.

Authors: D Moradpour; J R Wands
Journal: N Engl J Med Date: 1995-04-20 Impact factor: 91.245

5. Normal aminotransferase concentrations in patients with antibodies to hepatitis C virus.

Authors: S Bruno; S Rossi; M L Petroni; E Villa; M Zuin; M Podda
Journal: BMJ Date: 1994-03-12

6. Sexual transmission of hepatitis C virus.

Authors: D Bresters; E P Mauser-Bunschoten; H W Reesink; G Roosendaal; C L van der Poel; R A Chamuleau; P L Jansen; C J Weegink; H T Cuypers; P N Lelie
Journal: Lancet Date: 1993-07-24 Impact factor: 79.321

Review 7. Hepatitis C virus six years on.

Authors: C L van der Poel; H T Cuypers; H W Reesink
Journal: Lancet Date: 1994-11-26 Impact factor: 79.321

4. Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees.

Authors: V Sypsa; E Hadjipaschali; A Hatzakis
Journal: Eur J Epidemiol Date: 2001 Impact factor: 8.082

4 in total

Screening asymptomatic people at high risk for hepatitis C. The case for.

1. Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials.

2. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-alpha 2b.

3. Interferon and hepatitis C.

4. Understanding hepatitis B virus infection.

5. Normal aminotransferase concentrations in patients with antibodies to hepatitis C virus.

6. Sexual transmission of hepatitis C virus.

Review 7. Hepatitis C virus six years on.

8. Hepatitis C virus: epidemiology and genotypes in the north east of England.

9. Reliability of polymerase chain reaction for detection of hepatitis C virus.

10. Evaluation of third-generation screening and confirmatory assays for HCV antibodies.

1. Needle exchange programmes should do more to prevent transmission of hepatitis C virus.

2. Alanine aminotransferase assay to detect anti-HCV positive subjects in non-selected populations.

3. Assessment of hepatitis C infection in injecting drug users attending an addiction treatment clinic.

4. Prevalence, risk factors and evaluation of a screening strategy for chronic hepatitis C and B virus infections in healthy company employees.